Efficacy of long‐acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta‐analysis

Documenti analoghi

• Use of long‐acting cabotegravir and rilpivirine in people living with HIV : A prospective observational cohort study
  di: Ana Codonal, et al.
  Pubblicazione: (2026)
• Long‐acting cabotegravir and rilpivirine in people with HIV and obesity: Real‐world outcomes from the RELATIVITY cohort
  di: Jesús Troya, et al.
  Pubblicazione: (2026)
• Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort
  di: Jesús Troya, et al.
  Pubblicazione: (2025)
• Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV
  di: Kyle Ring, et al.
  Pubblicazione: (2025)
• Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine ( LA ‐I CAB  +  RPV ) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations
  di: Alexa Elias, et al.
  Pubblicazione: (2025)